Trial Profile

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BG 68501 (Primary) ; BGB-43395 (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BeOne Medicines

Most Recent Events

02 Jun 2025 According to a BeOne Medicines Media Release, initial results from this trial has been presented in the ASCO 2025.
02 Jun 2025 Results presented in the BeOne Medicines Media Release.
27 May 2025 According to BeOne Medicines media release, BeiGene is now called BeOne Medicines

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com